Table 12.
Cost-effectiveness analysis (US model)
| Study | Costs, US$mean (95% CI) | p Value | CUR, US$/QALY (95% CI) | ICUR, US$/QALY (95% CI) |
CURR, (95% CI) |
p Value | %CE30k | %CE50k | ICER US$/QALYG (95% CI) |
∆C1000
$ |
∆E1000
QALYG |
| Brandes153 | 22 106 (18 799 to 25 413) | 0.003 | 36 028 (28 866 to 43 189) | 3324 (−1280 to 7927) |
1.10 (0.96 to 1.25) |
0.472 | 3.01% | 84.02% | 34 727 (−12 095 to 81 549) |
6 728 332 | 193.8 |
| Strik155 | 46 775 (39 779 to 53 772) | <0.001 | 90 841 (76 123 to 105 558) | 58 136 (50 122 to 66 151) | 2.78 (2.45 to 3.11) |
<0.001 | 0.02% | 0,21% | 519 683 (−1009,423 to 2 048 790) |
31 397 527 | 60.4 |
| Abacioglu156 | 21 325 (18 135 to 24 515) | 0.007 | 49 579 (42 820 to 56 338) | 16 875 (12 433 to 21 317) | 1.52 (1.35 to 1.68) |
<0.001 | 0.17% | 51,27% | −109 798 (−426 187 to 206 591) |
5 947 408 | −54.2 |
| Berrocal157 | 24 799 (21 089 to 28 508) | <0.001 | 71 811 (56 003 to 87 619) | 39 107 (30 569 to 47 644) | 2.20 (1.89 to 2.51) |
<0.001 | 0.26% | 1,56% | −55 827 (−122 100 to 10 445) |
9 420 880 | −168.8 |
| WA (1–4) | 26 580 (22 604 to 30 555) | <0.001 | 59 276 (50 498 to 68 053) | 26 571 (21 289 to 31 853) | 1.81 (1.61 to 2.02) |
<0.001 | 0.08% | 2,34% | −380 229 (−2 447 832 to 1 687 373) |
11 201 761 | −29.5 |
| WA (2–4) | 26 760 (22 757 to 30 763) | <0.001 | 60 577 (51 756 to 69 398) | 27 873 (22 572 to 33 174) | 1.85 (1.64 to 2.06) |
<0.001 | 0.06% | 1,96% | −295 965 (−1 515 454 to 923 523) |
11 382 070 | −38.5 |
| WA (2–3)* | 26 901 (22 877 to 30 925) | <0.001 | 59 954 (51 427 to 68 481) | 27 249 (22 075 to 32 423) |
1.83 (1.63 to 2.04) |
<0.001 | 0.06% | 2,04% | −396 520 (−2 540 572 to 1 747 533) |
11 523 498 | −29.1 |
| Sahinbas23 | 15 378 (12 703 to 18 052) | 1.000 | 32 704 (27 215 to 38 193) | 0 | 1.00 (1.00 to 1.00) |
1.000 | 4.45% | 94,60% | 0 | 0 | 0.0 |
*Main comparator.
∆C1000, costs difference per 1000 patients; %CE50k, %CE at CET $50 000; CUR, cost-utility ratio; ∆E1000, effect difference per 1000 patients (QALY gained); ICER, incremental cost-effectiveness ratio; mEHT, modulated electrohyperthermia; RCUR, relative CUR; TMZ, temozolomide; QALY, quality-adjusted life-year; QALYG, QALY gained.